Inauhzin and Nutlin3 synergistically activate p53 and suppress tumor growth

References

• Leung AK, Sharp PA. MicroRNA functions in stress responses. Mol Cell 2010; 40:205 - 15; http://dx.doi.org/10.1016/j.molcel.2010.09.027; PMID: 20965416
   PubMed Web of Science ®Google Scholar
• Boominathan L. The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network. Cancer Metastasis Rev 2010; 29:613 - 39; http://dx.doi.org/10.1007/s10555-010-9257-9; PMID: 20922462
   PubMed Web of Science ®Google Scholar
• Speidel D. Transcription-independent p53 apoptosis: an alternative route to death. Trends Cell Biol 2010; 20:14 - 24; http://dx.doi.org/10.1016/j.tcb.2009.10.002; PMID: 19879762
   PubMed Web of Science ®Google Scholar
• Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69:1237 - 45; http://dx.doi.org/10.1016/0092-8674(92)90644-R; PMID: 1535557
   PubMed Web of Science ®Google Scholar
• Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362:857 - 60; http://dx.doi.org/10.1038/362857a0; PMID: 8479525
   PubMed Web of Science ®Google Scholar
• Chen J, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 1993; 13:4107 - 14; PMID: 7686617
   PubMed Web of Science ®Google Scholar
• Kruse JP, Gu W. Modes of p53 regulation. Cell 2009; 137:609 - 22; http://dx.doi.org/10.1016/j.cell.2009.04.050; PMID: 19450511
   PubMed Web of Science ®Google Scholar
• Wade M, Wang YV, Wahl GM. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol 2010; 20:299 - 309; http://dx.doi.org/10.1016/j.tcb.2010.01.009; PMID: 20172729
   PubMed Web of Science ®Google Scholar
• Kawai H, Lopez-Pajares V, Kim MM, Wiederschain D, Yuan ZM. RING domain-mediated interaction is a requirement for MDM2’s E3 ligase activity. Cancer Res 2007; 67:6026 - 30; http://dx.doi.org/10.1158/0008-5472.CAN-07-1313; PMID: 17616658
   PubMed Web of Science ®Google Scholar
• Linke K, Mace PD, Smith CA, Vaux DL, Silke J, Day CL. Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ 2008; 15:841 - 8; http://dx.doi.org/10.1038/sj.cdd.4402309; PMID: 18219319
   PubMed Web of Science ®Google Scholar
• Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993; 7:7A 1126 - 32; http://dx.doi.org/10.1101/gad.7.7a.1126; PMID: 8319905
   PubMed Web of Science ®Google Scholar
• Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J 1993; 12:461 - 8; PMID: 8440237
   PubMed Web of Science ®Google Scholar
• Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009; 9:749 - 58; http://dx.doi.org/10.1038/nrc2723; PMID: 19776744
   PubMed Web of Science ®Google Scholar
• Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res 1998; 26:3453 - 9; http://dx.doi.org/10.1093/nar/26.15.3453; PMID: 9671804
   PubMed Web of Science ®Google Scholar
• Shangary S, Wang S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 2009; 49:223 - 41; http://dx.doi.org/10.1146/annurev.pharmtox.48.113006.094723; PMID: 18834305
   PubMed Web of Science ®Google Scholar
• Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303:844 - 8; http://dx.doi.org/10.1126/science.1092472; PMID: 14704432
   PubMed Web of Science ®Google Scholar
• Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004; 10:1321 - 8; http://dx.doi.org/10.1038/nm1146; PMID: 15558054
   PubMed Web of Science ®Google Scholar
• Shangary S, Qin D, McEachern D, Liu M, Miller RS, Qiu S, et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A 2008; 105:3933 - 8; http://dx.doi.org/10.1073/pnas.0708917105; PMID: 18316739
   PubMed Web of Science ®Google Scholar
• Yang Y, Ludwig RL, Jensen JP, Pierre SA, Medaglia MV, Davydov IV, et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 2005; 7:547 - 59; http://dx.doi.org/10.1016/j.ccr.2005.04.029; PMID: 15950904
   PubMed Web of Science ®Google Scholar
• Reed D, Shen Y, Shelat AA, Arnold LA, Ferreira AM, Zhu F, et al. Identification and characterization of the first small molecule inhibitor of MDMX. J Biol Chem 2010; 285:10786 - 96; http://dx.doi.org/10.1074/jbc.M109.056747; PMID: 20080970
   PubMed Web of Science ®Google Scholar
• Kobet E, Zeng X, Zhu Y, Keller D, Lu H. MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. Proc Natl Acad Sci U S A 2000; 97:12547 - 52; http://dx.doi.org/10.1073/pnas.97.23.12547; PMID: 11070080
   PubMed Web of Science ®Google Scholar
• Ito A, Lai CH, Zhao X, Saito S, Hamilton MH, Appella E, et al. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J 2001; 20:1331 - 40; http://dx.doi.org/10.1093/emboj/20.6.1331; PMID: 11250899
   PubMed Web of Science ®Google Scholar
• Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997; 90:595 - 606; http://dx.doi.org/10.1016/S0092-8674(00)80521-8; PMID: 9288740
   PubMed Web of Science ®Google Scholar
• Li M, Luo J, Brooks CL, Gu W. Acetylation of p53 inhibits its ubiquitination by Mdm2. J Biol Chem 2002; 277:50607 - 11; http://dx.doi.org/10.1074/jbc.C200578200; PMID: 12421820
   PubMed Web of Science ®Google Scholar
• Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, Appella E, et al. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J 2002; 21:6236 - 45; http://dx.doi.org/10.1093/emboj/cdf616; PMID: 12426395
   PubMed Web of Science ®Google Scholar
• Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 2008; 13:454 - 63; http://dx.doi.org/10.1016/j.ccr.2008.03.004; PMID: 18455128
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zeng SX, Zhang Y, Zhang Y, Ding D, Ye Q, et al. A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53. EMBO Mol Med 2012; 4:298 - 312; http://dx.doi.org/10.1002/emmm.201100211; PMID: 22331558
   PubMed Web of Science ®Google Scholar
• Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA, Elgavish A, et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 2007; 67:6612 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-07-0085; PMID: 17638871
   PubMed Web of Science ®Google Scholar
• Jung-Hynes B, Nihal M, Zhong W, Ahmad N. Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition?. J Biol Chem 2009; 284:3823 - 32; http://dx.doi.org/10.1074/jbc.M807869200; PMID: 19075016
   PubMed Web of Science ®Google Scholar
• Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 2005; 123:437 - 48; http://dx.doi.org/10.1016/j.cell.2005.08.011; PMID: 16269335
   PubMed Web of Science ®Google Scholar
• Kitagawa M, Aonuma M, Lee SH, Fukutake S, McCormick F. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines. Oncogene 2008; 27:5303 - 14; http://dx.doi.org/10.1038/onc.2008.164; PMID: 18521084
   PubMed Web of Science ®Google Scholar
• Poyurovsky MV, Katz C, Laptenko O, Beckerman R, Lokshin M, Ahn J, et al. The C terminus of p53 binds the N-terminal domain of MDM2. Nat Struct Mol Biol 2010; 17:982 - 9; http://dx.doi.org/10.1038/nsmb.1872; PMID: 20639885
   PubMed Web of Science ®Google Scholar
• Dai JM, Wang ZY, Sun DC, Lin RX, Wang SQ. SIRT1 interacts with p73 and suppresses p73-dependent transcriptional activity. J Cell Physiol 2007; 210:161 - 6; http://dx.doi.org/10.1002/jcp.20831; PMID: 16998810
   PubMed Web of Science ®Google Scholar
• Verma R, Rigatti MJ, Belinsky GS, Godman CA, Giardina C. DNA damage response to the Mdm2 inhibitor nutlin-3. Biochem Pharmacol 2010; 79:565 - 74; http://dx.doi.org/10.1016/j.bcp.2009.09.020; PMID: 19788889
   PubMed Web of Science ®Google Scholar
• Valentine JM, Kumar S, Moumen A. A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation. BMC Cancer 2011; 11:79; http://dx.doi.org/10.1186/1471-2407-11-79; PMID: 21338495
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27 - 55; http://dx.doi.org/10.1016/0065-2571(84)90007-4; PMID: 6382953
   PubMedGoogle Scholar